Pasithea therapeutics announces positive safety review committee (src) recommendation from its ongoing phase 1 clinical trial of pas-004 in advanced cancer

– src recommended that the trial escalate to the next dose level of 30mg capsule – – no dose-limiting toxicities (dlt's) or rash observed to date – miami, april 10, 2025 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a clinical-stage biotechnology company developing pas-004, a next-generation macrocyclic mek inhibitor, for the treatment of neurofibromatosis type 1 (nf1) and other cancer indications, today announced that the external safety review committee recommended that the company's phase 1 clinical trial of pas-004 in advanced cancer should proceed to cohort 6, 30mg capsule, without modification. this recommendation was based on the review of the safety data from three patients from cohort 5 and the absence of any dose limiting toxicities (dlt's).
KTTA Ratings Summary
KTTA Quant Ranking